General
Johnson & Johnson COVID-19 vaccine under review by European Medicines Agency over blood clots
Europe’s drug regulator says it is reviewing rare blood clots in four people in the United States who received Johnson & Johnson’s COVID-19 vaccine.
Key points:
- Johnson & Johnson said it was aware of the rare reports of blood clots, and was working with regulators to assess the data
- The US Food and Drug Administration said it was aware of the reports, but they had “not found a causal relationship with vaccination”
- It follows an investigation of blood clots reported by some people given the AstraZeneca vaccine, which has prompted some countries to change their vaccine recommendations
The European Medicines Agency’s safety committee has also been looking at how AstraZeneca’s COVID-19 vaccine is associated with very rare cases of…
Continue Reading
-
Business23 hours agoWhy Macquarie expects this surging ASX 200 gold stock could leap another 40%
-
Business22 hours agoSilver reaches a 14-year high. Will it outperform the gold price this year?
-
Business22 hours ago3 ASX ETFs for beginners (and experts) to buy and forget
-
General23 hours ago‘Golden ticket’ visa for the rich fails to pay its way